Results 71 to 80 of about 2,577,172 (407)

Chronic Pain in Parkinson’s Disease: Prevalence, Sex Differences, Regional Anatomy and Comorbidities

Annals of Clinical and Translational Neurology, EarlyView.
Chronic pain affected 66.2% of 10,631 individuals with Parkinson's disease, with higher prevalence and severity in females. Pain most often involved the buttocks, lower back, neck, and knees, and was linked to depression, sleep disorders, and osteoarthritis.
Natalia S. Ogonowski, Freddy Chafota, Fangyuan Cao, Amanda Wei Yin Lim, Victor Flores‐Ocampo, Santiago Díaz‐Torres, Zuriel Ceja, Luis M. García‐Marín, Scott F. Farrell, Kishore R. Kumar, Jane Alty, George D. Mellick, Trung Thành Ngô, Miguel E. Rentería   +13 more
wiley   +1 more source

Opioid and cannabinoid receptors

Current Opinion in Neurobiology, 1994
Opioids and cannabinoids are two major classes of drugs with important clinical uses as well as significant side effects. Recently, the three major subtypes of opioid receptors, delta, kappa and mu, have been cloned. Both the endogenous cannabinoids and their receptors have also recently been cloned.
Terry Reisine, Michael J. Brownstein
openaire   +3 more sources

Placenta ingestion by rats enhances d- and k-opioid antinociception, but suppresses m-opioid antinociception [PDF]

, 2004
Ingestion of placenta or amniotic fluid produces a dramatic enhancement of centrally mediated opioid antinociception in the rat. The present experiments investigated the role of each opioid receptor type (m, d, k) in the antinociception-modulating ...
DiPirro, Jean M., Kristal, Dr. Mark B.
core  

Loss of μ-opioid receptor signaling in nociceptors, and not spinal microglia, abrogates morphine tolerance without disrupting analgesic efficacy

Nature Network Boston, 2016
Opioid pain medications have detrimental side effects including analgesic tolerance and opioid-induced hyperalgesia (OIH). Tolerance and OIH counteract opioid analgesia and drive dose escalation.
G. Corder, V. Tawfik, Dong Wang, Elizabeth I Sypek, Sarah A. Low, Jasmine R Dickinson, Chaudy Sotoudeh, J David Clark, B. Barres, Christopher J. Bohlen, G. Scherrer   +10 more
semanticscholar   +1 more source

Longitudinal Relationship Between Pain and Depression in People With Inflammatory Arthritis: A Narrative Review

Arthritis Care &Research, EarlyView.
As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox, Saeed Farooq, Helen Twohig, Ian C. Scott   +3 more
wiley   +1 more source

Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?

Journal of Clinical Pharmacy and Therapeutics, 2016
Optimal utilization of opioid analgesics is significantly limited by the central nervous system adverse effects and misuse/abuse potential of currently available drugs.
A. Albert-Vartanian, M. R. Boyd, A. L. Hall, S. J. Morgado, E. Nguyen, V. Nguyen, S. P. Patel, L. Russo, A. J. Shao, R. Raffa   +9 more
semanticscholar   +1 more source

Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health Administration

Arthritis Care &Research, Accepted Article.
Objective Though used frequently to treat flare, risk of chronic opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed chronic opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance

Biomedicines
The development of opioid tolerance in patients on long-term opioid analgesic treatment is an unsolved matter in clinical practice thus far. Dose escalation is required to restore analgesic efficacy, but at the price of side effects.
Anna Rita Galambos, Zsolt Tamás Papp, Imre Boldizsár, Ferenc Zádor, László Köles, Laszlo G. Harsing, Mahmoud Al-Khrasani   +6 more
doaj   +1 more source

Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide

Experimental and Molecular Medicine, 2018
Pain medicine: Boosting the potency of opioid analgesics A hormone known to weaken the pain-relieving effects of opioid drugs does so because of interaction between the hormone receptor and the opioid receptor.
Yin Yang, Qian Li, Qi-Hua He, Ji-Sheng Han, Li Su, You Wan   +5 more
doaj   +1 more source

Loperamide Inhibits Tachykinin NK3-Receptor-Triggered Serotonin Release Without Affecting NK2-Receptor-Triggered Serotonin Release From Guinea Pig Colonic Mucosa

Journal of Pharmacological Sciences, 2005
The effect of loperamide on tachykinin NK2- and NK3-receptor-mediated 5-HT outflow from guinea pig colonic mucosa was investigated in vitro. The selective tachykinin NK2-receptor agonist [β-Ala8]-neurokinin A4–10 (βAla-NKA) or the selective NK3-receptor ...
Shu-ichi Kojima, Masashi Ikeda, Yuichiro Kamikawa   +2 more
doaj   +1 more source